3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Promyelocytic, Acute
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
15
Cisplatin
9
Paclitaxel
6
Nivolumab
5
Fluorouracil
4
Carboplatin
4
atezolizumab
3
Sunitinib
3
Specimen Handling
3
Radiotherapy
3
Doxorubicin
3
pegfilgrastim
2
eribulin
2
cabozantinib
2
avelumab
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Ifosfamide
2
Docetaxel
2
CTLA-4 Antigen
2
Biopsy
2
vinflunine
1
vandetanib
1
tocilizumab
1
tamibarotene
1
rucaparib
1
rubitecan
1
romidepsin
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urethral Neoplasms
×
tamibarotene
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled